BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Brain Cancer Market – Forecast to 2030,’ thoroughly examines the Brain Cancer industry to provide essential data & information for the targeted readers.

Berkshire Sterile Manufacturing’s client, Fennec Pharmaceuticals Inc., received FDA approval of their drug product, PEDMARK – a sodium thiosulfate Injection with an indication to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Dr. Ingrid Delaet will join the company’s executive management team as Chief Regulatory Officer effective October 1, leading the regulatory affairs, quality assurance, medical writing, and program management teams. Dr. Delaet has served as Vice President of Regulatory Affairs at Neurocrine since January 2021.

Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.

Kubota Vision Inc., a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the Company and Joslin Diabetes Center have entered into a material transfer and collaboration agreement for our Patient Based Ophthalmology Suite, in-home optical coherence tomography device.

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October.

Backed by innovative new technology and industry-leading subject matter experts, SPARC Academy delivers on-demand, asynchronous EHR training

According to Nova one advisor, the global Cancer Immunotherapy market was valued at USD 82.10 billion in 2021 and it is expected to hit around USD 261.9 billion by 2030 with a CAGR of 13.11% during the forecast period 2022 to 2030.

Latest Study on “Horseradish Peroxidase Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Latest Study on “Psoriasis Treatment Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.